Eton Pharmaceuticals (NASDAQ:ETON) & Nexentis Technologies (NASDAQ:NXTS) Head-To-Head Review

Nexentis Technologies (NASDAQ:NXTS) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Risk and Volatility

Nexentis Technologies has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Earnings and Valuation

This table compares Nexentis Technologies and Eton Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexentis Technologies	$210,000.00	6.10	-$4.00 million	($96.07)	-0.01
Eton Pharmaceuticals	$105.59 million	14.82	-$4.60 million	$0.38	144.08

Nexentis Technologies has higher earnings, but lower revenue than Eton Pharmaceuticals. Nexentis Technologies is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

61.2% of Nexentis Technologies shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 6.5% of Nexentis Technologies shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Nexentis Technologies and Eton Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexentis Technologies	1	0	0	0	1.00
Eton Pharmaceuticals	0	2	4	0	2.67

Eton Pharmaceuticals has a consensus target price of $67.50, suggesting a potential upside of 23.29%. Given Eton Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Nexentis Technologies.

Profitability

This table compares Nexentis Technologies and Eton Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexentis Technologies	N/A	-304.79%	-178.91%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Summary

Eton Pharmaceuticals beats Nexentis Technologies on 11 of the 14 factors compared between the two stocks.

About Nexentis Technologies

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.